Deals
Sequoia's China Rival Targets Drug Startups That Can Go Global
- Respiratory drug developer Ark Biosciences may go public soon
- Up to six Qiming-backed biotech firms may have IPOs by 2022
This article is for subscribers only.
Qiming Venture Partners, a top Chinese tech investor that’s plowed $1 billion into healthcare companies since 2006, is training its focus on biotech startups it thinks have the best chance of taking on the world’s top drugmakers.
The venture capital firm, an early backer of Chinese phone maker Xiaomi Corp. that’s now a tech behemoth with a $37 billion market value, is being more selective about its biotech investments, said Managing Partner William Hu.